Gene:
SLC6A4
solute carrier family 6 (neurotransmitter transporter), member 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for SLC6A4

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA HTTLPR long form (L allele) N/A N/A N/A
No VIP available CA VA HTTLPR short form (S allele) N/A N/A N/A
No VIP available No VIP available VA L allele-rs25531C N/A N/A N/A
No VIP available No VIP available VA L allele-rs25531T N/A N/A N/A
No VIP available CA VA
rs1042173 NC_000017.10:g.28525011A>C, NC_000017.11:g.30197993A>C, NG_011747.2:g.42944T>G, NM_001045.5:c.*463T>G, XM_005258025.1:c.*463T>G, rs17825889, rs60303970
A > C
SNP
No VIP available No Clinical Annotations available VA
rs140700 NC_000017.10:g.28543389C>T, NC_000017.11:g.30216371C>T, NG_011747.2:g.24566G>A, NM_001045.5:c.838-155G>A, XM_005258025.1:c.964-155G>A, rs386530829, rs59205571
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2020933 NC_000017.10:g.28561755A>T, NC_000017.11:g.30234737A>T, NG_011747.2:g.6200T>A, NM_001045.5:c.-221+876T>A, XM_005258025.1:c.-95+876T>A, rs58019660
A > T
SNP
No VIP available CA VA
rs25531 NC_000017.10:g.28564346T>C, NC_000017.11:g.30237328T>C, NG_011747.2:g.3609A>G, NM_001045.5:c.-1936A>G, XM_005258025.1:c.-1810A>G, XR_934652.1:n.-225T>C, XR_934653.1:n.-225T>C, XR_934654.1:n.165+258T>C, XR_934655.1:n.-225T>C, rs2020931, rs35593448
T > C
SNP
No VIP available CA VA
rs57098334
(AGCCCACCC)9 > (AGCCCACCC)10
(AGCCCACCC)9 > (AGCCCACCC)12
microsatellite
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  HTT; OCD1; serotonin transporter 1; solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
Alternate Symbols:  5-HTT; SERT1
PharmGKB Accession Id: PA312

Details

Cytogenetic Location: chr17 : q11.2 - q11.2
GP mRNA Boundary: chr17 : 28521337 - 28562986
GP Gene Boundary: chr17 : 28518337 - 28572986
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Haplotype Overview

One serotonin transporter (SLC6A4) promoter polymorphism (often named: HTTLPR) consists of varies numbers of copies of a 20-23bp imperfect repeat sequence [Article:16642437]. The HTTLPR is a length variation polymorphism. Most literature reports that the short form (s allele) is generated by a deletion with an overall length of 44bp compared to the long form (l allele) based on the original articles of discovery [Articles:8632190, 8788073, 8929413]. Additional short and long alleles were identified [Articles:9605856, 10673766].

The polymorphism is generally detected by PCR with oligonucleotide primers flanking the HTTLPR region and a subsequent length discrimination using an agarose gel.

The rs25531 A/G SNP is found in the promoter region and alters the functional effect of the HTTLPR. A number of studies distinguish the HTTLPR long allele that contains the rs25531 G allele vs. the long allele containing the rs25531 A allele [Article:16642437]. The HTTLPR long allele that contains the rs25531 G allele is often grouped with the HTTLPR short allele.

Murphy et al. reviews the complications regarding the detection and functional interpretation of the polymorphisms in the SLC6A4 promoter region including the indel polymorphism [Article:23336038]. The review reports a frequency of about 22% for S/LG alleles in Caucasians and about 60% in Asians [Article:23336038].

Source: PharmGKB

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
    Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.
  1. Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics
    Genes involved in serotonin synthesis, release, reuptake, and in mediation of the antidepressant effect of selective serotonin reuptake inhibitors (SSRI) in human brain.
  1. Venlafaxine Pathway, Pharmacokinetics
    Stylized cells depicting the metabolism and mechanism of action of venlafaxine.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Curated Information ?

Publications related to SLC6A4: 140

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Possible biomarkers modulating haloperidol efficacy and/or tolerability. Pharmacogenomics. 2016. Porcelli Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is there a role for pharmacogenetics in the treatment of panic disorder?. Pharmacogenomics. 2015. Caldirola Daniela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. Pharmacogenomics. 2015. Martinucci Irene, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics. 2015. Bauer Isabelle E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015. Helton Sarah G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. Pharmacogenomics. 2015. Roche Daniel Jo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry. Pharmacogenomics. 2015. Levran Orna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert opinion on drug metabolism & toxicology. 2014. Fabbri Chiara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014. Zai Gwyneth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. British journal of clinical pharmacology. 2014. Reynolds Gavin P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and genomics. 2013. Hall-Flavin Daniel K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Human psychopharmacology. 2013. Ng Chee, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLC6A4 Polymorphisms and Age of Onset in Late-life Depression on Treatment Outcomes with Citalopram: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2013. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013. López-Rodríguez Rosario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013. Severino Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. Journal of child and adolescent psychopharmacology. 2013. Rotberg Benyamin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. Journal of clinical psychopharmacology. 2013. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of clinical response to risperidone. Pharmacogenomics. 2013. Llerena Adrián, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology. 2013. Myung Woojae, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. The pharmacogenomics journal. 2012. Lohoff F W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry. 2012. Dreimüller N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics. 2012. Narasimhan Sneha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. Journal of affective disorders. 2012. Mushtaq Dhuha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. The pharmacogenomics journal. 2012. Almoguera B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. European journal of clinical pharmacology. 2011. Ishiguro Shin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology. 2012. Won Eun-Soo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2011. Strohmaier Jana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region. The pharmacogenomics journal. 2011. Hu Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. European archives of psychiatry and clinical neuroscience. 2011. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. The American journal of psychiatry. 2011. Johnson Bankole A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. Journal of affective disorders. 2010. Gudayol-Ferré Esteve, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. Journal of clinical psychopharmacology. 2010. Lenze Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. Journal of psychiatric research. 2010. Kohlrausch Fabiana B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. Journal of psychopharmacology (Oxford, England). 2010. Umene-Nakano Wakako, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010. Becker Mara L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressive treatment. European archives of psychiatry and clinical neuroscience. 2010. Zobel Astrid, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. Journal of affective disorders. 2010. Yevtushenko Olga O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. International clinical psychopharmacology. 2010. Dombrovski Alexandre Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2010. Laje Gonzalo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. The pharmacogenomics journal. 2010. Keers R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry research. 2010. Vázquez-Bourgon Javier, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter gene, depressive symptoms, and interleukin-6. Circulation. Cardiovascular genetics. 2009. Su Shaoyong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clinical pharmacology and therapeutics. 2009. Oberlander T F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Molecular psychiatry. 2009. Bull S J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms. Neuropsychobiology. 2010. Serretti Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clinical pharmacology and therapeutics. 2009. Daskalakis Z J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Human psychopharmacology. 2009. Yoshimura Reiji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatric genetics. 2009. Gressier Florence, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology. 2009. Min Wenjiao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. European journal of clinical pharmacology. 2009. Saeki Yoshinori, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy. 2009. Thomas Kelan L H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLC6A4 variation and citalopram response. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2009. Mrazek D A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2009. Maron Eduard, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. Journal of affective disorders. 2009. Alexopoulos George S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009. Perroud Nader, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Moderation of antidepressant response by the serotonin transporter gene. The British journal of psychiatry : the journal of mental science. 2009. Huezo-Diaz Patricia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant response: an update. Human genomics. 2009. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Human psychopharmacology. 2009. Bishop Jeffrey R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular epidemiology of major depressive disorder. Environmental health and preventive medicine. 2009. Kiyohara Chikako, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. The pharmacogenomics journal. 2009. Wilkie M J V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenetics and genomics. 2009. Ruhé Henricus G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. Journal of thrombosis and haemostasis : JTH. 2008. Abdelmalik N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PloS one. 2009. Hesselson Stephanie E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics. 2008. Kronenberg Sefi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacogenetics and potential application in personalized medicine. Current drug metabolism. 2008. Zhou Shu-Feng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature genetics. 2008. Allen Nicole C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug target identification using side-effect similarity. Science (New York, N.Y.). 2008. Campillos Monica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2008. Tharoor Hema, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genetic testing. 2008. Dogan Ozlem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Towards a transgenic model of Huntington's disease in a non-human primate. Nature. 2008. Yang Shang-Hsun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphism and bleeding time during SSRI therapy. British journal of clinical pharmacology. 2008. Hougardy Dahlia M C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. Journal of psychiatry & neuroscience : JPN. 2008. Lotrich Francis E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2008. Tanaka Misuzu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2008. Bozina Nada, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics in modern psychiatry. Psychiatria Danubina. 2007. Mihaljević-Peles Alma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science (New York, N.Y.). 2007. Zhou Zheng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of general psychiatry. 2007. Hu Xian-Zhang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert opinion on investigational drugs. 2007. Chen Zhengming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. International clinical psychopharmacology. 2007. Smits Kim, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve. 2007. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. The pharmacogenomics journal. 2007. Kirchheiner J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Progress in neuro-psychopharmacology & biological psychiatry. 2006. Kim Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA : the journal of the American Medical Association. 2006. Kim Hyeran, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. American journal of human genetics. 2006. Hu Xian-Zhang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. Pharmacogenomics. 2006. Popp Johannes, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics and antidepressant drugs. Annals of medicine. 2006. Binder Elisabeth B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005. Perna Giampaolo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. The pharmacogenomics journal. 2006. Hong C-J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The serotonin transporter gene polymorphism is not associated with smoking behavior. The pharmacogenomics journal. 2006. Trummer O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sequence analysis of the serotonin transporter and associations with antidepressant response. Biological psychiatry. 2005. Kraft Jeffrey B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2005. Chen Fenghua, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International clinical psychopharmacology. 2005. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. Journal of psychopharmacology (Oxford, England). 2005. Arias Bárbara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Current pharmaceutical design. 2005. Bymaster Frank P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of general psychiatry. 2004. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science (New York, N.Y.). 2004. Ansorge Mark S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2004. Serretti Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology. 2004. Durham L Kathryn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2004. Matsushita Sachio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Molecular psychiatry. 2004. Smits K M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological psychiatry. 2003. Perlis Roy H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the serotonin transporter gene with sudden infant death syndrome: a haplotype analysis. American journal of medical genetics. Part A. 2003. Weese-Mayer Debra E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucocorticoid-regulated human serotonin transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic region. Journal of neurochemistry. 2003. Glatz K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. Journal of clinical psychopharmacology. 2003. Arias Bárbara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. The pharmacogenomics journal. 2003. Rousseva A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002. Takahashi Hitoshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry research. 2002. Ito K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter promoter polymorphism, peripheral indexes of serotonin function, and personality measures in families with alcoholism. American journal of medical genetics. 2002. Stoltenberg Scott F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2002. Yoshida Keizo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular psychiatry. 2002. Yu Y W-Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder. Molecular psychiatry. 2002. Kim S-J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. The pharmacogenomics journal. 2002. Di Bella D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological psychiatry. 2001. Zanardi R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2001. Bymaster F P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nature genetics. 2001. Glatt C E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2000. Pollock B G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology. 2000. Whale R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of clinical psychopharmacology. 2000. Zanardi R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Molecular psychiatry. 2000. Nakamura M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000. Kim D K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proceedings of the National Academy of Sciences of the United States of America. 1999. MacKenzie A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter (5-HTT) and gamma-aminobutyric acid receptor subunit beta3 (GABRB3) gene polymorphisms are not associated with autism in the IMGSA families. The International Molecular Genetic Study of Autism Consortium. American journal of medical genetics. 1999. Maestrini E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS letters. 1999. Fiskerstrand C E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter gene (HTTLPR) is not in linkage disequilibrium with prepubertal and early adolescent bipolarity. Biological psychiatry. 1999. Geller B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular psychiatry. 1998. Smeraldi E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1998. Hanna G L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence of linkage between the serotonin transporter and autistic disorder. Molecular psychiatry. 1997. Cook E H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981. Brogden R N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ftp://ftpguest:4guest@ftp.pharmgkb.org/download/PKB_N00000011.html. [URL:ftp://ftpguest:4guest@ftp.pharmgkb.org/download/PKB_N00000011.html]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ftp://ftpguest:4guest@ftp.pharmgkb.org/download/PKB_N00000012.html. [URL:ftp://ftpguest:4guest@ftp.pharmgkb.org/download/PKB_N00000012.html]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
http://pharmacogenetics.ucsf.edu/public-results/sert/. [URL:http://pharmacogenetics.ucsf.edu/public-results/sert/]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
http://pharmacogenetics.ucsf.edu/public-results/vmat2/. [URL:http://pharmacogenetics.ucsf.edu/public-results/vmat2/]

LinkOuts

NCBI Gene:
6532
OMIM:
164230
182138
607834
UCSC Genome Browser:
NM_001045
RefSeq RNA:
NM_001045
RefSeq Protein:
NP_001036
RefSeq DNA:
NG_011747
NT_010799
HuGE:
SLC6A4
Comparative Toxicogenomics Database:
6532
ModBase:
P31645
HumanCyc Gene:
HS03126
HGNC:
11050

Common Searches